Valproate vs levetiracetam in juvenile myoclonic epilepsy: systematic review and meta-analysis
Epilepsy & Behavior · 2026-11 · 184 · 111208
DOI: 10.1016/j.yebeh.2026.111208 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Epilepsy & Behavior, 2026-11. Verfasst von Lavínia Voss Agra und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Federal University of Alagoas, Brazil. Electronic address: lavinia.agra@famed.ufal.br. Hauptthemen laut MEDLINE: Myoclonic Epilepsy, Juvenile, Levetiracetam, Anticonvulsants, Valproic Acid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
INTRODUCTION: Juvenile myoclonic epilepsy (JME) is a genetic generalized epilepsy syndrome with onset typically in adolescence and a chronic course requiring long-term antiseizure medications (ASMs). Valproate (VPA) is the most effective treatment for seizure control in JME but use is limited by metabolic, cognitive, and teratogenic adverse effects (AEs). Levetiracetam (LEV) is an alternative ASM when VPA is contraindicated or not tolerated. Comparisons of the efficacy and long-term tolerability of VPA and LEV remain limited. METHODS: We conducted a systematic review and meta-analysis using PRISMA guidelines and the Cochrane Handbook. We searched PubMed, Embase, and the Cochrane Library from inception through January 2026 for studies in JME patients comparing LEV and VPA, and included randomized controlled trials and comparative observational studies with ≥ 6 months of follow-up. Primary outcomes were seizure remission and ASM failure or treatment discontinuation. Secondary outcomes included, memory impairment, weight gain or obesity, dizziness, and overall AEs. Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using random-effects models. Heterogeneity was assessed using the I2 statistic. RESULTS: Seven studies encompassing 1,009 patients were included. VPA was associated with higher pooled seizure remission rates compared with LEV (344 of 574 vs. 169 of 390; RR 1.44, 95% CI 1.27-1.63); however, substantial heterogeneity (I2 = 88.4%) limits confidence in this finding. VPA was associated with a lower risk of drug failure or treatment discontinuation (RR 0.68, 95% CI 0.54-0.86), with no heterogeneity (I2 = 0.0%). VPA was also associated with a higher risk of memory impairment (RR 5.37, 95% CI 2.05-14.04; I2 = 74.5%) and weight gain or obesity (RR 6.40, 95% CI 3.64-11.26; I2 = 35.9%). No significant differences were observed between treatments regarding dizziness (RR 0.91, 95% CI 0.61-1.37; I2 = 21.2%). Sensitivity analyses confirmed the robustness of the pooled estimates. CONCLUSION: VPA was associated with higher seizure remission rates and lower treatment discontinuation compared with LEV; however, these findings must be interpreted with caution given the substantial heterogeneity, the predominance of observational studies, and the serious risk of bias identified in most included studies VPA also demonstrated lower rates of treatment discontinuation, despite a higher burden of cognitive impairment and weight gain. No relevant differences were observed regarding dizziness. Large-scale randomized trials with standardized outcome definitions and longer follow-up are needed to define the comparative risk-benefit profiles of LEV and VPA in JME.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Federal University of Alagoas, Brazil. Electronic address: lavinia.agra@famed.ufal.br.
- Department of Medicine, Cesmac University Center, Maceió/AL, Brazil.
- Department of Medicine, Federal University of Alagoas, Brazil.
- Porto Alegre Epilepsy Surgery Program, Neurology and Neurosurgery Services, Hospital São Lucas, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, Brazil.
- Alberto Antunes University Hospital, Faculty of Medicine, Federal University of Alagoas (UFAL), EBSERH, Maceió, Brazil.
- Department of Neurology, NYU Langone Medical Center, New York, NY, USA.
Zitieren
APA
Agra, L. V., Machado Borges, M. C., de Azevedo Oliveira, L. C. F., de Carvalho, I. M. T., Silva, J. A., Aguiar-Barros, A. B. P., Brêda-Cavalcante, L. B., Suruagy-Motta, R. F. O., Guido Santos, V. C., de Albuquerque, A. L. A., Martins, W. A., Gameleira, F. T., & Devinsky, O. (2026). Valproate vs levetiracetam in juvenile myoclonic epilepsy: systematic review and meta-analysis. Epilepsy & Behavior, 184, 111208. https://doi.org/10.1016/j.yebeh.2026.111208
Vancouver
Agra LV, Machado Borges MC, de Azevedo Oliveira LCF, de Carvalho IMT, Silva JA, Aguiar-Barros ABP, et al. Valproate vs levetiracetam in juvenile myoclonic epilepsy: systematic review and meta-analysis. Epilepsy & Behavior. 2026;184:111208. doi:10.1016/j.yebeh.2026.111208
BibTeX
@article{Agra2026,
author = {Agra, Lavínia Voss and Machado Borges, Marcela Caracas and de Azevedo Oliveira, Luiz Carlos Fonseca and de Carvalho, Isabela Montenegro Tenório and Silva, Júlia Agra and Aguiar-Barros, Ana Beatriz P and Brêda-Cavalcante, Leonardo Beltrão and Suruagy-Motta, Ricardo F O and Guido Santos, Victor Costa and de Albuquerque, Ana Leticia Amorim and Martins, William Alves and Gameleira, Fernando Tenório and Devinsky, Orrin},
title = {Valproate vs levetiracetam in juvenile myoclonic epilepsy: systematic review and meta-analysis},
journal = {Epilepsy & Behavior},
year = {2026},
volume = {184},
pages = {111208},
doi = {10.1016/j.yebeh.2026.111208}
}
EUVIMED